Phase 2 Ankylosing Spondylitis Trial, Recruiting NCT06222671 Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Condition: Ankylosing Spondylitis
Back to Ankylosing Spondylitis

Phase 2 Ankylosing Spondylitis Trial, Recruiting

NCT06222671
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are at least 18 years old (both men and women can apply)
  • You have been diagnosed with a type of spinal arthritis called axial spondyloarthritis, based on recognised medical guidelines
  • You have signs of inflammation in your body, shown either by an MRI scan or a blood test result (C-reactive protein)
  • You have a back pain score of 4 or more out of 10 at the start of the trial

Who may not be able to join:

  • You have other inflammatory diseases that are not well-controlled
  • Your blood tests or other medical tests show results that are considered significantly abnormal (confirm with trial site)
  • You currently have an active Hepatitis B, Hepatitis C, or HIV infection, confirmed by a screening test
  • You have a history of cancer
  • You have a known or suspected history of a weakened immune system
  • You are known to be allergic or sensitive to a medicine called mometasone furoate nasal spray, or to the placebo used in this trial

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Qinghong Zhou, BS, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Phone: 18911301578

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Registry
ClinicalTrials.gov
Start date
22 March 2024
Est. completion
22 September 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The Percentage of Participants Who Achieved an Assessment of Spondylo Arthritis International Society (ASAS) 40 Response

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov